CEL-SCI Enrolls 20 Patients In Aug. In Multikine Phase III Study - Quick Facts

(RTTNews) - CEL-SCI Corp. (CVM) announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine during August 2014. This brings the total study enrollment to 252 patients.

The objective of the Multikine Phase III study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care, or SOC, vs. subjects who are treated with SOC only.

"Given that summer months generally have a slower rate of enrollment for clinical trials, our goal was to maintain the enrollment level compared to the three months prior to the summer. We continue to add more centers and countries to the study. As we head into the fall, we believe the pace of patient enrollment will further increase," said CEL-SCI CEO Geert Kersten.